Real-World Effectiveness and Safety of Tofacitinib for Alopecia Areata: A Retrospective Cohort Study of 202 Patients

Tofacitinib was found to be a safe and effective treatment for moderate-to-severe alopecia areata (AA) in a real-world setting, as evidenced by a retrospective cohort study of 202 patients over 18 months. The study showed that 55.9% of patients achieved a 50% reduction in their Severity of Alopecia Tool (SALT) scores, 42.6% achieved a 75% reduction, and 29.2% achieved a 90% reduction. Factors such as longer duration of AA and higher baseline SALT scores were associated with slower response to treatment. No serious adverse events were reported, although many patients also received systemic corticosteroids or low-dose oral minoxidil. Further randomized controlled studies are recommended to determine the optimal treatment regimen.